| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | 0.035 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | lapatinib | FIMM | pan-cancer | AAC | 0.043 | 0.8 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.8 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | 0.0089 | 0.8 |